[Current indications of low-molecular-weight heparins].
Low-molecular-weight heparins (LMWH) have different properties than non-fractionated heparins. Bioavailability is better after subcutaneous administration and a longer halflife allows a single daily injection. Efficacy is equivalent for postoperative thromboembolism prophylaxis for all types of surgery. In most reports, low-molecular-weight heparins are more effective than non fractionated heparin and lead to fewer episodes of hemorrhage and thrombocytopenia. For treatment of deep vein thrombosis, low-molecular-weight heparins are as effective as non-fractionated heparins after two, or even one, daily injection without hemostasis tests. Other on-going studies are evaluating LMWH indications in pulmonary embolism, artery disease, pregnancy or other medical conditions.
Vignes
S
S
Service de Médecine Interne (Pr Rouffy), Hôpital St-Louis, Paris.
Meyer
G
G
Marjanovic
Z
Z
Farge-Bancel
D
D
D002561:Cerebrovascular Disorders / Q000628:therapy; D003327:Coronary Disease / Q000628:therapy; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011183:Postoperative Complications; D011247:Pregnancy; D013923:Thromboembolism / Q000517:prevention & control* / Q000628:therapy; D013924:Thrombophlebitis / Q000517:prevention & control / Q000628:therapy
D006495:Heparin, Low-Molecular-Weight
Indications actuelles des héparines de bas poids moléculaire.